Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis

Cerdá, 2017, Association of state recreational marijuana laws with adolescent marijuana use, JAMA Pediatr, 171, 142, 10.1001/jamapediatrics.2016.3624 Black, 2019, Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis, Lancet Psychiatry, 6, 995, 10.1016/S2215-0366(19)30401-8 Moreau, 1973 D'Souza, 2004, The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis, Neuropsychopharmacology, 29, 1558, 10.1038/sj.npp.1300496 Barkus, 2011, Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study, J Psychopharmacol, 25, 1462, 10.1177/0269881110382465 Morgan, 2018, Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function, Transl Psychiatry, 8, 181, 10.1038/s41398-018-0191-x Morrison, 2009, The acute effects of synthetic intravenous Δ9tetrahydrocannabinol on psychosis, mood and cognitive functioning, Psychol Med, 39, 1607, 10.1017/S0033291709005522 Morrison, 2011, Disruption of frontal θ coherence by Δ9tetrahydrocannabinol is associated with positive psychotic symptoms, Neuropsychopharmacology, 36, 827, 10.1038/npp.2010.222 Ranganathan, 2012, Naltrexone does not attenuate the effects of intravenous Δ9tetrahydrocannabinol in healthy humans, Int J Neuropsychopharmacol, 15, 1251, 10.1017/S1461145711001830 Bhattacharyya, 2009, Modulation of mediotemporal and ventrostriatal function in humans by Δ9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis, Arch Gen Psychiatry, 66, 442, 10.1001/archgenpsychiatry.2009.17 Bhattacharyya, 2015, Impairment of inhibitory control processing related to acute psychotomimetic effects of cannabis, Eur Neuropsychopharmacol, 25, 26, 10.1016/j.euroneuro.2014.11.018 Bossong, 2009, Δ9-tetrahydrocannabinol induces dopamine release in the human striatum, Neuropsychopharmacology, 34, 759, 10.1038/npp.2008.138 D'Souza, 2008, Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis, Neuropsychopharmacology, 33, 2505, 10.1038/sj.npp.1301643 D'Souza, 2009, Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans, Psychopharmacology, 202, 569, 10.1007/s00213-008-1333-2 D'Souza, 2012, Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ9THC in humans, Neuropsychopharmacology, 37, 1632, 10.1038/npp.2012.8 Kleinloog, 2012, Does olanzapine inhibit the psychomimetic effects of Δ9tetrahydrocannabinol?, J Psychopharmacol, 26, 1307, 10.1177/0269881112446534 Liem-Moolenaar, 2010, Central nervous system effects of haloperidol on THC in healthy male volunteers, J Psychopharmacol, 24, 1697, 10.1177/0269881109358200 Pertwee, 2008, The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and Δ9tetrahydrocannabivarin, Br J Pharmacol, 153, 199, 10.1038/sj.bjp.0707442 Englund, 2013, Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment, J Psychopharmacol, 27, 19, 10.1177/0269881112460109 Schubart, 2011, Cannabis with high cannabidiol content is associated with fewer psychotic experiences, Schizophr Res, 130, 216, 10.1016/j.schres.2011.04.017 Morgan, 2008, Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis, Br J Psychiatry, 192, 306, 10.1192/bjp.bp.107.046649 Zuardi, 2006, Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug, Braz J Med Biol Res, 39, 421, 10.1590/S0100-879X2006000400001 McGuire, 2018, Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial, Am J Psychiatry, 175, 225, 10.1176/appi.ajp.2017.17030325 Bhattacharyya, 2010, Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology, Neuropsychopharmacology, 35, 764, 10.1038/npp.2009.184 Mueller, 2016, Effects and interaction of delta-9-tetrahydrocannabidiol and cannabidiol on psychopathology, neurocognition, and endocannabinoids in serum of healthy volunteers: influence on psychopathology, Neuropsychopharmacology, 41, S589 Potter, 2008, Potency of Δ9THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology, J Forensic Sci, 53, 90, 10.1111/j.1556-4029.2007.00603.x Overall, 1962, The brief psychiatric rating scale, Psychol Rep, 10, 799, 10.2466/pr0.1962.10.3.799 Kay, 1989, The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation, Br J Psychiatry Suppl, 155, 59, 10.1192/S0007125000291514 Stroup, 2000, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group, JAMA, 283, 2008, 10.1001/jama.283.15.2008 Higgins, 2011, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, 10.1136/bmj.d5928 Islam, 2016, Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis, Neuroepidemiology, 47, 181, 10.1159/000454881 2011 Brugger, 2017, Heterogeneity and homogeneity of regional brain structure in schizophrenia: a meta-analysis, JAMA Psychiatry, 74, 1104, 10.1001/jamapsychiatry.2017.2663 Bowden, 2011, Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics, BMC Med Res Methodol, 11, 41, 10.1186/1471-2288-11-41 Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Gurillo, 2015, Does tobacco use cause psychosis? Systematic review and meta-analysis, Lancet Psychiatry, 2, 718, 10.1016/S2215-0366(15)00152-2 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 Karcher, 2019, Genetic predisposition vs individual-specific processes in the association between psychotic-like experiences and cannabis use, JAMA Psychiatry, 76, 87, 10.1001/jamapsychiatry.2018.2546 Ohlsson, 1980, Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking, Clin Pharmacol Ther, 28, 409, 10.1038/clpt.1980.181 Bell, 1992, The positive and negative syndrome scale and the brief psychiatric rating scale: reliability, comparability, and predictive validity, J Nerv Ment Dis, 180, 723, 10.1097/00005053-199211000-00007 Bhattacharyya, 2012, Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of δ-9-tetrahydrocannabinol on midbrain and striatal function, Mol Psychiatry, 17, 1152, 10.1038/mp.2011.187 Fusar-Poli, 2009, Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing, Arch Gen Psychiatry, 66, 95, 10.1001/archgenpsychiatry.2008.519 Radhakrishnan, 2015, GABA deficits enhance the psychotomimetic effects of Δ9-THC, Neuropsychopharmacology, 40, 2047, 10.1038/npp.2015.58 Skosnik, 2008, Affect processing and positive syndrome schizotypy in cannabis users, Psychiatry Res, 157, 279, 10.1016/j.psychres.2007.02.010 Bloomfield, 2014, Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms, Biol Psychiatry, 75, 470, 10.1016/j.biopsych.2013.05.027 Fabritius, 2013, Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint, Anal Bioanal Chem, 405, 9791, 10.1007/s00216-013-7412-1 Noble, 2019, Acute cannabis toxicity, Clin Toxicol, 57, 735, 10.1080/15563650.2018.1548708 Hirvonen, 2018, Decreased cannabinoid CB1 receptors in male tobacco smokers examined with positron emission tomography, Biol Psychiatry, 84, 715, 10.1016/j.biopsych.2018.07.009 Kaivosaari, 2011, N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases, Xenobiotica, 41, 652, 10.3109/00498254.2011.563327 Stout, 2014, Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review, Drug Metab Rev, 46, 86, 10.3109/03602532.2013.849268 Borgan, 2019, In vivo availability of cannabinoid 1 receptor levels in patients with first-episode psychosis, JAMA Psychiatry, 10.1001/jamapsychiatry.2019.1427 Di Forti, 2019, The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study, Lancet Psychiatry, 6, 427, 10.1016/S2215-0366(19)30048-3 Borgan, 2019, The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study, Mol Psychiatry